Funding the Cell & Gene Therapy Boom
The ascent of cell and gene therapies (CGT) is commonly regarded as one of the momentous turning points in the history of the pharmaceuticals industry. Not only do innovative therapies…
Louis was the Senior Analyst and Editor-in-Chief from 2013 to 2019. He currently collaborates with PharmaBoardroom as external editor. Having directed pharmaceuticals & life science projects across 4 continents, he has published over 30 country reports as well as produced analytical studies on trends in blockchain, Pharma M&A and biotechnology. He has a professional background in consultan more...
The ascent of cell and gene therapies (CGT) is commonly regarded as one of the momentous turning points in the history of the pharmaceuticals industry. Not only do innovative therapies…
Emerging cell and gene therapies herald immense clinical value for patients, society, and healthcare systems: carrying the potential to offer life-changing solutions for people with few or no alternative treatments.…
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s…
Some of the more entrepreneurial Moroccan local laboratories have spotted an opening to leverage their knowledge of Sub Saharan African markets and to act as a conduit and partner for…
Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most of whom seemed more intent on…
Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real…
In some respects, is it perhaps the medtech sector that has most to be excited about in the UAE’s domestic market, given the country’s unrelenting enthusiasm for connected devices, the…
The UAE’s distinctive willingness to embrace innovation and the ‘can-do’ spirit of authorities marks the country out as worthy of attention as an initial product launch platform. “Along with…
Digital health deal values in biopharma jumped to USD 6.4 billion in 2019, largely thanks to software company Dassault Systemes Americas Corp.’s USD 5.9 billion acquisition of health tech company…
With so many wild predictions being bandied around about AI’s potential to radically transform healthcare for the better, it is easy to lose sight of the fact that materialization of…
As data and information proliferate at an exponential pace, many industries have turned to artificial intelligence to make sense of this information and deliver meaningful insights that can enhance performance.…
On the supply side, AI appears to herald the prospect of de-risking the drug discovery process and doing away with many of the traditional time-consuming approaches at a juncture when…
See our Cookie Privacy Policy Here
